IRL201104

DRUG4 trials

Sponsors

Revolo Biotherapeutics

Conditions

Eosinophilic EsophagitisHealthy VolunteerSeasonal Allergic Rhinitis

Phase 1

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

CompletedNCT04748536

Revolo BiotherapeuticsHealthy Volunteer

Start: 2021-01-29End: 2021-04-05Updated: 2021-04-26

Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers

CompletedNCT05921591

Revolo BiotherapeuticsHealthy Volunteer

Start: 2023-05-26End: 2023-09-12Updated: 2023-09-28

Phase 2

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

CompletedNCT05084963

Revolo BiotherapeuticsEosinophilic Esophagitis

Start: 2021-10-29End: 2022-10-24Updated: 2025-05-21

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

CompletedNCT05098522

Revolo BiotherapeuticsSeasonal Allergic Rhinitis

Start: 2021-11-04End: 2023-03-27Updated: 2023-05-03

Related Papers

S460 Efficacy and Safety of IRL201104, a Novel Peptide Immunomodulator, in a Phase 2a, Double-Blind, Placebo-Controlled Multi-Center Study in Patients With Active Eosinophilic Esophagitis

The American Journal of Gastroenterology2023-10-013 citations